Anti-inflammatory Effect of Cannabidiol and Palmitoylethanolamide Containing Topical Formulation on Skin in a 12-O-Tetradecanoylphorbol-13-Acetate-Induced Dermatitis Model in Mice
Laboratory studyOther animalsTopicalWith cannabidiol
This study tested palmitoylethanolamide together with cannabidiol. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- 35 mice, randomised into treatment groups, with one ear treated with the irritant TPA and the other ear as control
- Dose used in the study
- Topical formulation containing 0.9% cannabidiol and PEA, compared against a potent topical corticosteroid (mometasone)
- Duration
- Ear edema measured at 24 and 48 hours after treatment
- What was measured
- Ear thickness (oedema) after TPA irritant challenge, comparing the CBD/PEA formulation, mometasone, and untreated control
What the authors reported
This laboratory study found:
- The CBD/PEA formulation reduced ear oedema by 51.27% at 24 hours and 65.69% at 48 hours.
- Mometasone reduced oedema by 89.82% at 24 hours and 98.25% at 48 hours.
- Untreated control oedema fell by 26.32% and 44.21% naturally.
- Both treated groups differed significantly from baseline and from control (P < 0.05).
Limits of this study
A mouse model of induced dermatitis; it cannot show effect in people. One author was salary-funded by a Pfizer independent grant, two by CQ Science; the remaining authors declare no conflicts.
Source
PubMed 33654018 · doi:10.1097/DER.0000000000000722
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.